Program
plamotamab
Also written as “Plamotamab” and “XmAb13676”.
Its studies are mostly in Arthritis, Rheumatoid · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Large B-Cell, Diffuse, led by Xencor.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xencor | 31 open or running | phase 2since Apr 4, 2022 | Sep 14, 2016 | Jun 2028phase 1 · NCT07230353 |
Also a collaborator on its studies: icon-clinical-research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2016First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT02924402 · 154 enrolled · United States, France, Korea, Republic of and more
- Apr 4, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05328102 · 3 enrolled · United States, France, Spain
- Oct 1, 2025Phase 1 study in Arthritis, RheumatoidNCT07230353 · 68 planned · Georgia, Moldova, New Zealand
Ahead
- Jun 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07230353
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230353Arthritis, Rheumatoid · Georgia, Moldova, New Zealand | 1 | Recruiting | Jun 2028 | 68 |
| NCT05328102Lymphoma, Large B-Cell, Diffuse · United States, France, Spain | 2 | Terminated | Feb 21, 2023 | 3 |
| NCT02924402Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Korea, Republic of and more | 1 | Completed | Apr 2024 | 154 |
How it is read
Names in the registry
- “Plamotamab”, 2 entries
- “XmAb13676”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.